These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 21191854)
1. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials. Zhang Y; Mietlowski W; Chen B; Wang Y J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854 [TBL] [Abstract][Full Text] [Related]
2. Optimal two-stage randomized multinomial designs for Phase II oncology trials. Sun LZ; Chen C; Patel K J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690 [TBL] [Abstract][Full Text] [Related]
3. Optimal and minimax three-stage designs for phase II oncology clinical trials. Chen K; Shan M Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337 [TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. Pond GR; Abbasi S Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687 [TBL] [Abstract][Full Text] [Related]
5. Optimizing randomized phase II trials assessing tumor progression. Stone A; Wheeler C; Carroll K; Barge A Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129 [TBL] [Abstract][Full Text] [Related]
6. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470 [No Abstract] [Full Text] [Related]
7. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Taylor JM; Braun TM; Li Z Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208 [TBL] [Abstract][Full Text] [Related]
8. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trials with a prospective control. Jung SH Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688 [TBL] [Abstract][Full Text] [Related]
10. Optimal designs for two-arm, phase II clinical trial design with multiple constraints. Mayo MS; Mahnken JD; Soong SJ J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252 [TBL] [Abstract][Full Text] [Related]
11. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Sharma MR; Maitland ML; Ratain MJ Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363 [TBL] [Abstract][Full Text] [Related]
12. Multinomial phase II cancer trials incorporating response and early progression. Zee B; Melnychuk D; Dancey J; Eisenhauer E J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698 [TBL] [Abstract][Full Text] [Related]
13. Optimising the design of phase II oncology trials: the importance of randomisation. Ratain MJ; Sargent DJ Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773 [TBL] [Abstract][Full Text] [Related]
14. A three-outcome design for randomized comparative phase II clinical trials. Hong S; Wang Y Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879 [TBL] [Abstract][Full Text] [Related]
15. Admissible two-stage designs for phase II cancer clinical trials. Jung SH; Lee T; Kim K; George SL Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389 [TBL] [Abstract][Full Text] [Related]
16. Adaptive two-stage designs in phase II clinical trials. Banerjee A; Tsiatis AA Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547 [TBL] [Abstract][Full Text] [Related]
17. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials. Masaki N; Koyama T; Yoshimura I; Hamada C J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436 [TBL] [Abstract][Full Text] [Related]
18. A flexible multi-stage design for phase II oncology trials. Tan MT; Xiong X Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328 [TBL] [Abstract][Full Text] [Related]
19. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253 [TBL] [Abstract][Full Text] [Related]
20. An adjustment for patient heterogeneity in the design of two-stage phase II trials. Sposto R; Gaynon PS Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]